Develops self-assembling small-molecule targeted protein degraders that form inside cells—one moiety engages an E3 ligase and the other binds the target—enabling oral dosing, improved tissue/tumor penetration and CNS accessibility. Operates a combinatorial, high-throughput reusable platform for building an internal drug pipeline and collaborative CURE-PRO development programs.